These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28168767)

  • 21. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.
    ; Wing RR
    Arch Intern Med; 2010 Sep; 170(17):1566-75. PubMed ID: 20876408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.
    Mannucci E; Ognibene A; Cremasco F; Bardini G; Mencucci A; Pierazzuoli E; Ciani S; Fanelli A; Messeri G; Rotella CM
    Diabet Med; 2000 Oct; 17(10):713-9. PubMed ID: 11110504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial.
    Wing RR; Espeland MA; Clark JM; Hazuda HP; Knowler WC; Pownall HJ; Unick J; Wadden T; Wagenknecht L;
    Diabetes Care; 2016 Aug; 39(8):1345-55. PubMed ID: 27271190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Association of Cardiometabolic, Diet and Lifestyle Parameters With Plasma Glucagon-like Peptide-1: An IMI DIRECT Study.
    Eriksen R; White MC; Dawed AY; Perez IG; Posma JM; Haid M; Sharma S; Prehn C; Thomas EL; Koivula RW; Bizzotto R; Mari A; Giordano GN; Pavo I; Schwenk JM; De Masi F; Tsirigos KD; Brunak S; Viñuela A; Mahajan A; McDonald TJ; Kokkola T; Rutters F; Beulens J; Muilwijk M; Blom M; Elders P; Hansen TH; Fernandez-Tajes J; Jones A; Jennison C; Walker M; McCarthy MI; Pedersen O; Ruetten H; Forgie I; Holst JJ; Thomsen HS; Ridderstråle M; Bell JD; Adamski J; Franks PW; Hansen T; Holmes E; Frost G; Pearson ER
    J Clin Endocrinol Metab; 2024 Aug; 109(9):e1697-e1707. PubMed ID: 38686701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.
    Franz MJ; Boucher JL; Rutten-Ramos S; VanWormer JJ
    J Acad Nutr Diet; 2015 Sep; 115(9):1447-63. PubMed ID: 25935570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes.
    Lugari R; Dei Cas A; Ugolotti D; Finardi L; Barilli AL; Ognibene C; Luciani A; Zandomeneghi R; Gnudi A
    Horm Metab Res; 2002 Mar; 34(3):150-4. PubMed ID: 11972305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naïve type 2 diabetic patients.
    de Luis DA; Aller R; Izaola O; Bachiller R
    J Endocrinol Invest; 2015 Feb; 38(2):143-7. PubMed ID: 25200998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effectiveness and safety of liraglutide in clinical practice.
    Ponzani P
    Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in inflammatory biomarkers after successful lifestyle intervention in obese children.
    Garanty-Bogacka B; Syrenicz M; Goral J; Krupa B; Syrenicz J; Walczak M; Syrenicz A
    Endokrynol Pol; 2011; 62(6):499-505. PubMed ID: 22144215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
    Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lifestyle intervention reduces body weight and improves cardiometabolic risk factors in worksites.
    Salinardi TC; Batra P; Roberts SB; Urban LE; Robinson LM; Pittas AG; Lichtenstein AH; Deckersbach T; Saltzman E; Das SK
    Am J Clin Nutr; 2013 Apr; 97(4):667-76. PubMed ID: 23426035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
    Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
    Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of lifestyle intervention on cardiometabolic risk factors: results of the POWER-UP trial.
    Vetter ML; Wadden TA; Chittams J; Diewald LK; Panigrahi E; Volger S; Sarwer DB; Moore RH;
    Int J Obes (Lond); 2013 Aug; 37 Suppl 1(0 1):S19-24. PubMed ID: 23921777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth.
    Kim JY; Michaliszyn SF; Nasr A; Lee S; Tfayli H; Hannon T; Hughan KS; Bacha F; Arslanian S
    Diabetes Care; 2016 Aug; 39(8):1431-9. PubMed ID: 27293201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.
    Wright JL; Schenk JM; Gulati R; Beatty SJ; VanDoren M; Lin DW; Porter MP; Morrissey C; Dash A; Gore JL; Etzioni R; Plymate SR; Neuhouser ML
    Cancer; 2024 Jun; 130(12):2108-2119. PubMed ID: 38353455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes.
    de Jonge C; Rensen SS; Verdam FJ; Vincent RP; Bloom SR; Buurman WA; le Roux CW; Schaper NC; Bouvy ND; Greve JW
    Obes Surg; 2013 Sep; 23(9):1354-60. PubMed ID: 23526068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meal replacement reduces insulin requirement, HbA1c and weight long-term in type 2 diabetes patients with >100 U insulin per day.
    Kempf K; Schloot NC; Gärtner B; Keil R; Schadewaldt P; Martin S
    J Hum Nutr Diet; 2014 Apr; 27 Suppl 2():21-7. PubMed ID: 23909831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients.
    Umeda LM; Silva EA; Carneiro G; Arasaki CH; Geloneze B; Zanella MT
    Obes Surg; 2011 Jul; 21(7):896-901. PubMed ID: 21559794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.